How Does Ofev Affect Survival in Pulmonary Fibrosis?
Ofev (nintedanib) slows lung function decline in idiopathic pulmonary fibrosis (IPF) patients but does not improve overall survival rates. In the Phase 3 INPULSIS trials, Ofev reduced the annual rate of forced vital capacity (FVC) decline by 107 mL compared to placebo over 52 weeks, a key marker of disease progression.[1][2] Median survival from diagnosis in IPF remains around 3-5 years regardless of treatment, as Ofev primarily delays progression rather than extending life.[3]
What Do Key Clinical Trials Show on Mortality?
INPULSIS-1 and INPULSIS-2 trials (1,247 patients) reported on-treatment mortality of 5.5% for Ofev versus 7.8% for placebo at 52 weeks, but this did not reach statistical significance for overall survival benefit.[1][4] A pooled analysis confirmed no significant difference in time to first acute IPF exacerbation or death.[2] Long-term extension data (INPULSIS-ON) showed 3-year survival rates of about 50-60% in treated patients, aligning with natural IPF history.[5]
Does Ofev Help in Progressive Pulmonary Fibrosis Beyond IPF?
In the Phase 3 INBUILD trial for progressive fibrosing interstitial lung diseases (non-IPF), Ofev slowed FVC decline by 80 mL/year but showed no survival advantage, with similar all-cause mortality rates to placebo over 52 weeks.[6] Real-world studies echo this, with no clear mortality reduction.[7]
What Survival Factors Matter More Than Ofev Alone?
Baseline FVC, age under 65, and no acute exacerbations predict better outcomes. Combining Ofev with pirfenidone is common but lacks randomized data on additive survival effects; observational studies suggest stabilized lung function but unchanged median survival.[3][8] Lung transplant remains the only definitive survival extender for eligible patients.
How Does Ofev Compare to Pirfenidone?
Pirfenidone also slows FVC decline similarly (per ASCEND and CAPACITY trials) with no proven survival benefit.[9] Head-to-head trials are absent, but meta-analyses show comparable efficacy in delaying progression, not mortality.[10]
[1]: INPULSIS trial publication
[2]: FDA Ofev label
[3]: ATS/ERS IPF guidelines
[4]: INPULSIS pooled analysis
[5]: INPULSIS-ON extension
[6]: INBUILD trial
[7]: Real-world IPF cohort
[8]: Ofev-pirfenidone combo review
[9]: Pirfenidone ASCEND trial
[10]: Nintedanib vs pirfenidone meta-analysis